Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients

Leucèmia mieloide crònica; Resposta a imatinib; Telòmer

Detalhes bibliográficos
Autores: Estrada, Natalia, Beier, Fabian, García, Olga, Morales, Cristian, Boqué, Concepción, Sagüés-Serrano, Miquel, Ventura Ferreira, Monica, Vallansot, Rolando, Marcé, Silvia, Brümmendorf, Tim, Cabezón, Marta, Xicoy, Blanca, Zamora, Lurdes
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Recursos:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/9225
Acesso em linha:https://hdl.handle.net/11351/9225
Access Level:acceso abierto
Palavra-chave:Leucèmia mieloide crònica
Telòmer
Imatinib
DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Cycle::Cell Division::Telomere Homeostasis
CHEMICALS AND DRUGS::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::ciclo celular::división celular::homeostasis telomérica
COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::amidas::benzamidas::mesilato de imatinib
id ES_a377e1924e9b628ea1be94cdafd4f6aa
oai_identifier_str oai:scientiasalut.gencat.cat:11351/9225
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
spellingShingle Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
Estrada, Natalia
Leucèmia mieloide crònica
Telòmer
Imatinib
DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Cycle::Cell Division::Telomere Homeostasis
CHEMICALS AND DRUGS::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::ciclo celular::división celular::homeostasis telomérica
COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::amidas::benzamidas::mesilato de imatinib
title_short Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_full Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_fullStr Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_full_unstemmed Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
title_sort Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
dc.creator.none.fl_str_mv Estrada, Natalia
Beier, Fabian
García, Olga
Morales, Cristian
Boqué, Concepción
Sagüés-Serrano, Miquel
Ventura Ferreira, Monica
Vallansot, Rolando
Marcé, Silvia
Brümmendorf, Tim
Cabezón, Marta
Xicoy, Blanca
Zamora, Lurdes
author Estrada, Natalia
author_facet Estrada, Natalia
Beier, Fabian
García, Olga
Morales, Cristian
Boqué, Concepción
Sagüés-Serrano, Miquel
Ventura Ferreira, Monica
Vallansot, Rolando
Marcé, Silvia
Brümmendorf, Tim
Cabezón, Marta
Xicoy, Blanca
Zamora, Lurdes
author_role author
author2 Beier, Fabian
García, Olga
Morales, Cristian
Boqué, Concepción
Sagüés-Serrano, Miquel
Ventura Ferreira, Monica
Vallansot, Rolando
Marcé, Silvia
Brümmendorf, Tim
Cabezón, Marta
Xicoy, Blanca
Zamora, Lurdes
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Estrada N] Myeloid Neoplasms Research Group, Josep Carreras Leukemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Spain. [Xicoy B, Garcia O, Marcé S, Cabezón M, Zamora L] Myeloid Neoplasms Research Group, Josep Carreras Leukemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Spain. Hematology Department, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Spain. [Beier F, Ventura Ferreira MS, Brümmendorf TH] Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, Uniklinik RWTH Aachen University, Germany. [Morales C] Core-Hematology Department, Clinical Laboratory ICS-Metropolitan Nord, Hospital Germans Trias i Pujol, Badalona, Spain. [Boqué C] Hematology Department, Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain. [Sagüés M] Department d’Hematologia, Institut Català d'Oncologia Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Vallansot R] Hematology Department, Institut Català d'Oncologia-Hospital Universitari Joan XXIII, Tarragona, Spain
Hospital Universitari de Girona Dr Josep Trueta
dc.subject.none.fl_str_mv Leucèmia mieloide crònica
Telòmer
Imatinib
DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Cycle::Cell Division::Telomere Homeostasis
CHEMICALS AND DRUGS::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::ciclo celular::división celular::homeostasis telomérica
COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::amidas::benzamidas::mesilato de imatinib
topic Leucèmia mieloide crònica
Telòmer
Imatinib
DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Cycle::Cell Division::Telomere Homeostasis
CHEMICALS AND DRUGS::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::ciclo celular::división celular::homeostasis telomérica
COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::amidas::benzamidas::mesilato de imatinib
description Leucèmia mieloide crònica; Resposta a imatinib; Telòmer
publishDate 2021
dc.date.none.fl_str_mv 2021
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/9225
url https://hdl.handle.net/11351/9225
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Hemasphere;5(12)
https://doi.org/10.1097/hs9.0000000000000657
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Lippincott, Williams & Wilkins
publisher.none.fl_str_mv Lippincott, Williams & Wilkins
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415400025882624
spelling Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia PatientsEstrada, NataliaBeier, FabianGarcía, OlgaMorales, CristianBoqué, ConcepciónSagüés-Serrano, MiquelVentura Ferreira, MonicaVallansot, RolandoMarcé, SilviaBrümmendorf, TimCabezón, MartaXicoy, BlancaZamora, LurdesLeucèmia mieloide crònicaTelòmerImatinibDISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myelogenous, Chronic, BCR-ABL PositivePHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cell Cycle::Cell Division::Telomere HomeostasisCHEMICALS AND DRUGS::Organic Chemicals::Amides::Benzamides::Imatinib MesylateENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positivaFENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::ciclo celular::división celular::homeostasis teloméricaCOMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::amidas::benzamidas::mesilato de imatinibLeucèmia mieloide crònica; Resposta a imatinib; TelòmerLeucemia mieloide crónica; Respuesta a imatinib; TelómeroChronic myelogenous leukemia; Imatinib; TelomereTyrosine kinase inhibitors have dramatically changed the outcome of chronic myeloid leukemia (CML), and nowadays, one of the main treatment goals is the achievement of deep molecular responses (DMRs), which can eventually lead to therapy discontinuation approaches. Few biological factors at diagnosis have been associated with this level of response. Telomere length (TL) in peripheral blood cells of patients with CML has been related to disease stage, response to therapy and disease progression, but little is known about its role on DMR. In this study, we analyzed if age-adjusted TL (referred as "delta-TL") at diagnosis of chronic phase (CP)-CML might correlate with the achievement of DMR under first-line imatinib treatment. TL from 96 CP-CML patients had been retrospectively analyzed at diagnosis by monochrome multiplex quantitative PCR. We observed that patients with longer age-adjusted telomeres at diagnosis had higher probabilities to achieve DMR with imatinib than those with shortened telomeres (P = 0.035 when delta-TL was studied as a continuous variable and P = 0.047 when categorized by the median). Moreover, patients carrying long telomeres also achieved major molecular response significantly earlier (P = 0.012). This study provides proof of concept that TL has a role in CML biology and when measured at diagnosis of CP-CML could help to identify patients likely to achieve DMR to first-line imatinib treatment.This work was in part supported by a grant from Instituto de Salud Carlos III through the project “PI16/01200” (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe”/”Investing in your future”) as well as by the grant “Bolsa de ayuda económica para la innovación científica” and the grant “Becas de Investigación” both from Fundación Española de Hematología y Hemoterapia (FEHH). Figure 3. Cumulative incidence (95% CI) of MMR at 24 months from imatinib start. CI = confidence interval Downloaded from http://journals.lww.com/hemasphere by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCy wCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/Lippincott, Williams & WilkinsInstitut Català de la Salut[Estrada N] Myeloid Neoplasms Research Group, Josep Carreras Leukemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Spain. [Xicoy B, Garcia O, Marcé S, Cabezón M, Zamora L] Myeloid Neoplasms Research Group, Josep Carreras Leukemia Research Institute, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona, Spain. Hematology Department, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Institut de Recerca Contra la Leucèmia Josep Carreras, Universitat Autònoma de Barcelona, Spain. [Beier F, Ventura Ferreira MS, Brümmendorf TH] Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, Uniklinik RWTH Aachen University, Germany. [Morales C] Core-Hematology Department, Clinical Laboratory ICS-Metropolitan Nord, Hospital Germans Trias i Pujol, Badalona, Spain. [Boqué C] Hematology Department, Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, Spain. [Sagüés M] Department d’Hematologia, Institut Català d'Oncologia Hospital Universitari de Girona Doctor Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Vallansot R] Hematology Department, Institut Català d'Oncologia-Hospital Universitari Joan XXIII, Tarragona, SpainHospital Universitari de Girona Dr Josep Trueta202320232021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/9225Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésHemasphere;5(12)https://doi.org/10.1097/hs9.0000000000000657Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/92252026-06-12T09:38:37Z
score 15,811543

Registos relacionados